Assessing muscle mass and strength in patients with cirrhosis
Prospective Observational Cohort Survey to Assess the Prevalence and Development of Sarcopenia and the Correlation of Muscle Mass and Outcome in Patients With Cirrhosis by Skeletal Muscle Ultrasound.
This study is testing how muscle mass and strength change in people with cirrhosis to see how it affects their daily lives and health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Antwerp Academic / other |
| Locations | 1 site (Edegem, Antwerpen) |
| Trial ID | NCT06345547 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to investigate the prevalence and progression of sarcopenia in patients with cirrhosis at the University Hospital of Antwerp. Participants will undergo ultrasound assessments of muscle mass in both upper and lower limbs, handgrip strength measurements, and malnutrition screenings. Additionally, a quality of life questionnaire will be administered to evaluate the impact of sarcopenia on daily living. The study will analyze correlations between muscle mass, clinical outcomes, and the etiology of cirrhosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with cirrhosis who are receiving follow-up care at the University Hospital of Antwerp.
Not a fit: Patients who have made a decision to stop further treatment or those with recent complete remission of malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of sarcopenia in cirrhosis, leading to improved management and treatment strategies for affected patients.
How similar studies have performed: Other studies have shown success in using ultrasound to assess muscle mass in various populations, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of cirrhosis and follow-up in the University Hospital of Antwerp Exclusion Criteria: * known patient will against participation in the study or against the measures applied in the study * a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours * no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
Where this trial is running
Edegem, Antwerpen
- University Hospital Antwerp — Edegem, Antwerpen, Belgium (Recruiting)
Study contacts
- Principal investigator: Karolien Dams, MD — University Hospital, Antwerp
- Study coordinator: Karolien Dams, MD
- Email: karolien.dams@uza.be
- Phone: +3238213635
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.